Search for: "Pfizer Inc."
Results 1241 - 1260
of 1,379
Sorted by Relevance
|
Sort by Date
1 May 2024, 1:18 pm
”[20] The court explained that a defendant need not know of the AKS specifically — or intend to violate the AKS — they only have to know that the conduct was unlawful in some way.[21] The McKesson court emphasized that, in its view, this definition was fully in line with the Second Circuit’s 2022 decision in Pfizer Inc. v. [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
9 Feb 2016, 6:27 am
Pfizer, Inc., 2000 WL 1738645 (S.D.N.Y. [read post]
7 Oct 2010, 5:00 am
Pfizer Inc., 249 F.R.D. 248, 254 n.8 (E.D. [read post]
15 Jul 2010, 2:39 pm
Wyeth, Inc., 613 F. [read post]
7 Feb 2008, 10:46 am
Medtronic, Inc., 231 F.3d 216, 230 (6th Cir. 2001).Kemp concluded that the purported "violations" before it were not violations at all - but merely reflected Plaintiffs' incorrect reading of FDA requirements. [read post]
22 Jan 2009, 2:06 am
Pfizer Inc., 358 F.3d 659, 661 (9th Cir. 2004) (same; physician considered warning inappropriate) (applying California law).Under these facts, if Conte were an ordinary prescription drug product liability case, plaintiff would have been out of court and out of luck, just like Motus. [read post]
8 Oct 2008, 11:50 am
Pfizer, Inc., 153 S.W.3d 758, 762 (Ky. 2004) (not a holding, but dictum suggesting broad comment k application).Louisiana: Kinney v. [read post]
29 Dec 2010, 12:54 pm
Wyeth, Inc. v. [read post]
28 Mar 2008, 6:00 am
: (Afro-IP),If education and pricing policy fail, says Adobe in Nigeria, we can still sue: (Afro-IP),South African arm of Chrysler objects to advertisement by Indian vehicle maker Mahindra and Mahindra that uses the term "jeep": (Afro-IP), (Spicy IP),Kenya’s call for anti-counterfeit legislation… amongst other changes: (Afro-IP),Kenya: Shared computer use raises privacy, confidentiality issues: (Afro-IP)AustraliaChanges to grace period for trade mark renewal:… [read post]
23 Jan 2020, 10:37 pm
The phosphodiesterases 5 inhibitor medications (PDE5i) seem to arouse the litigation propensities of the lawsuit industry. [read post]
4 Jan 2010, 2:22 pm
Eric Affeldt, chief executive, ClubCorp Inc. [read post]
28 Apr 2011, 3:18 pm
By now Restatement (Second) of Torts §402A (1965) is so old as to be thought of as somewhat antediluvian. [read post]
19 Aug 2008, 10:35 pm
Vioxx came on the market in June 1999, after rival Pfizer Inc.'s Celebrex. [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with Sandoz over… [read post]
30 Sep 2011, 3:14 am
[Link] Dynamics Inc. is seeking a patent attorney with an EE degree, to work at their Pittsburgh location. [read post]
19 Aug 2008, 10:35 pm
Vioxx came on the market in June 1999, after rival Pfizer Inc.'s Celebrex. [read post]
2 Mar 2022, 10:39 am
For example, Holmes’ added the Pfizer logo to company reports, which led large investors, like Walgreens, to believe that the blood tests had been validated by the pharmaceutical giant. [read post]
5 May 2009, 5:57 am
The cases, both on alleged failure to warn of the risk of suicide, include one against Glaxo over Paxil and one against New York-based Pfizer Inc. over Zoloft. [read post]
28 Oct 2011, 10:06 am
The Moderator: Ronald Staudt, IIT Chicago-Kent College of Law The Panelists: Toby Brown, Vinson & Elkins; Lisa Damon, Seyfarth Shaw LLP; Paul Lippe, Legal OnRamp; Mark Ohringer, Jones Lang LaSalle Americas, Inc.; and Ellen Rosenthal, Pfizer Lisa Damon, Seyfarth Shaw LLP Seyfarth Lean Background: About 6 years ago, clients started asking for alternative fees. [read post]
